STADA Arzneimittel Overview
- Year Founded
-
1895
- Status
-
Private
- Employees
-
11,500
- Latest Deal Type
-
Debt - Acquisition
- Financing Rounds
-
29
- Investments
-
43
STADA Arzneimittel General Information
Description
Manufacturer of pharmaceuticals and consumer healthcare products. The company focuses on generics, specialty pharmaceuticals, and over-the-counter brands sold in various countries, thereby ensuring access to affordable and high-quality healthcare solutions worldwide.
Contact Information
Website
www.stada.comCorporate Office
- Stadastraße 2-18
- 61118 Bad Vilbel
- Germany
Corporate Office
- Stadastraße 2-18
- 61118 Bad Vilbel
- Germany
STADA Arzneimittel Timeline
STADA Arzneimittel Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
STADA Arzneimittel Comparisons
Industry
Financing
Details
STADA Arzneimittel Competitors (36)
One of STADA Arzneimittel’s 36 competitors is Evonile Pharma, a Private Equity-Backed company based in Mumbai, India.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Evonile Pharma | Private Equity-Backed | Mumbai, India | ||||
| Sun Pharmaceutical Industries | Corporation | Mumbai, India | ||||
| Berlin-Chemie | Corporation | Berlin, Germany | ||||
| Eisai (Germany) | Corporation | Frankfurt, Germany | ||||
| GSK | Corporation | London, United Kingdom |
STADA Arzneimittel Patents
STADA Arzneimittel Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026013152-A1 | Pharmaceutical composition comprising olaparib | Pending | 09-Jul-2024 | ||
| WO-2025156193-A1 | Palbociclib dosage form | Pending | 25-Jan-2024 | ||
| WO-2025158014-A1 | Palbociclib dosage form | Pending | 25-Jan-2024 | ||
| EP-4574137-A1 | Method for producing a stabilized diamine oxidase lyophilisate and pharmaceutical dosage form | Inactive | 19-Dec-2023 | ||
| US-20250195623-A1 | Method for producing a stabilized diamine oxidase lyophilisate and pharmaceutical dosage form | Pending | 19-Dec-2023 | A61K38/44 |
STADA Arzneimittel Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
STADA Arzneimittel Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
STADA Arzneimittel Investments & Acquisitions (43)
STADA Arzneimittel’s most recent deal was a Buyout/LBO with Orifarm (Vitamins, Minerals and Supplements Portfolio in Denmark) for . The deal was made on 24-Jun-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Orifarm (Vitamins, Minerals and Supplements Portfolio in Denmark) | 24-Jun-2026 | Buyout/LBO | Buildings and Property | ||
| Sanofi (Healthcare Brands) | 31-Dec-2023 | Buyout/LBO | Pharmaceuticals | ||
| Nemus Lex | 20-Dec-2022 | Buyout/LBO | Personal Products | ||
| Sanofi (16 Consumer Healthcare Brands) | 28-Jun-2021 | Merger/Acquisition | Pharmaceuticals | ||
| Lobsor Pharmaceuticals | 01-Sep-2020 | Buyout/LBO | Therapeutic Devices |
STADA Arzneimittel Exits (8)
STADA Arzneimittel’s most recent exit was on 01-Jan-2013 from STADA Pymepharco. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| STADA Pymepharco | 01-Jan-2013 | Completed |
|
||
| STADA Pymepharco | 01-Jan-2010 | Completed |
|
||
| STADA Pymepharco | 01-Jan-2008 | Completed |
|
||
| LipoNova | 26-Feb-2004 | Completed |
|
||
| Sirton Pharmaceuticals | 17-May-2002 | Merger/Acquisition | Completed |
STADA Arzneimittel Affiliates
Subsidiaries (14)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Lobsor Pharmaceuticals | Uppsala, Sweden | 2013 | |
| Nemus Lex | Zagreb, Croatia | 2004 | |
| Eg Labo - Laboratoires Eurogeneric | Issy-Les-Moulineaux, France | 1996 | |
| Stada Service Holding | Breda, Netherlands | 1991 | |
| Walmark | Trinec, Czech Republic | 1990 |
STADA Arzneimittel FAQs
-
When was STADA Arzneimittel founded?
STADA Arzneimittel was founded in 1895.
-
Where is STADA Arzneimittel headquartered?
STADA Arzneimittel is headquartered in Bad Vilbel, Germany.
-
What is the size of STADA Arzneimittel?
STADA Arzneimittel has 11,500 total employees.
-
What industry is STADA Arzneimittel in?
STADA Arzneimittel’s primary industry is Pharmaceuticals.
-
Is STADA Arzneimittel a private or public company?
STADA Arzneimittel is a Private company.
-
What is STADA Arzneimittel’s current revenue?
The current revenue for STADA Arzneimittel is .
-
How much funding has STADA Arzneimittel raised over time?
STADA Arzneimittel has raised $354M.
-
Who are STADA Arzneimittel’s investors?
CapVest Partners, FS KKR Capital BDC, Future Standard (Philadelphia), Bain Capital, and Cinven have invested in STADA Arzneimittel.
-
Who are STADA Arzneimittel’s competitors?
Evonile Pharma, Sun Pharmaceutical Industries, Berlin-Chemie, Eisai (Germany), and GSK are some of the 36 competitors of STADA Arzneimittel.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
